Amgen's weight-loss drug progress strengthens its pipeline, while its recent outperformance suggests technical resilience. Strong fundamentals and sector tailwinds support a bullish stance.

Positive news on Amgen's weight-loss drug and bullish analyst theories are driving optimism. However, mixed market reactions indicate cautious sentiment.

Long-term risks include pipeline execution and competitive pressures, but Amgen's innovation and market position justify a neutral outlook. Regulatory and clinical hurdles remain key watchpoints.

Technical indicators show Amgen holding support levels amid broader market weakness, with volume trends suggesting accumulation. Short-term momentum favors a bullish bias.